Ams OSRAM Swings To Q3 Profit On A Disposal Gain, Guides Q4

ams-OSRAM AG reported a Q3 net profit of €319M (€2.97/share) vs. a loss of €28M (€0.28/share) a year earlier, driven by a disposal gain. Revenue fell 3% to €829M. Adjusted EBITDA dropped to €135M. The company expects Q4 revenue of €750M-€850M and an adjusted EBITDA margin of 16.0% ±1.5%.

Original reporting
Published Nov 13, 2026, 7:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 7:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ams OSRAM Swings To Q3 Profit On A Disposal Gain, Guides Q4 — source image
Decision brief

The 30-second read

$AMSBearishMed
01

Why it matters

The earnings beat and guidance provide fresh data for valuation models, but the modest outlook may limit upside.

02

Market read

First report of ams-OSRAM's Q3 profit and guidance, offering actionable insight for traders with exposure to European tech stocks.

03

What to watch

The disposal gain is non-recurring; future growth depends on core sensor portfolio performance.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

ams-OSRAM AG, a Swiss-listed semiconductor company, announced its Q3 earnings and Q4 outlook after a year of losses.

Company-level read

Ticker impact

$AMSBearishHigh confidence
Context

ams-OSRAM reported Q3 profit of €319M and provided Q4 guidance, marking a turnaround from a loss.

Expected impact

likely slight downside pressure as investors digest modest guidance

Evidence & confidence

Profit beat is positive, but revenue decline and modest guidance may limit upside, leading to a small sell-off.

Market effects

Signals potential softness in the optical sensor market, may affect peers in the semiconductor sector.

European semiconductor stocks could see modest pressure.

Limited, primarily relevant to investors in European tech hardware.

Counterpoint

The profit turnaround could be a one-off from the disposal gain; underlying business may still be weak.

Key entities

  • ams-OSRAM AG

    Swiss semiconductor firm reporting Q3 results.

Related articles

$AMSHighAI 8/10

Why is ams OSRAM stock sliding today?

ams OSRAM (AOS) shares fell 6.6% to CHF 15.67 after Q3 2026 results and Q4 guidance. Q4 revenue forecast (€750M-€850M) and adjusted EBITDA margin (16% ±1.5%) missed expectations. Q3 revenue (€829M) beat consensus, but adjusted EBITDA dropped 19% YoY. The stock declined on cautious outlook and margin compression.

$AMSMed

ams-OSRAM AG (AMS) Guides Q4 Revenue to EUR 750–850M

ams-OSRAM AG reported Q3 2023 revenue of EUR 829M, up 3% sequentially but down 3% year-on-year. The company expects Q4 2023 revenue of EUR 750–850M and an adjusted EBITDA margin of 16.0% ± 1.5 percentage points. The guidance comes amid portfolio reshaping and semiconductor growth.

$AMSMed

American Shared Hospital Services Reports Third Quarter and Nine-Month 2026 Financial Results

AMERICAN SHARED HOSPITAL SERVICES (AMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 American Shared Hospital Services Reports Third Quarter and Nine-Month 2026 Financial Results Third Quarter Revenue Increased 6% to $7.6 Million; Direct Patient Services Revenue Increased 14% Nine-Month Revenue Increased 14% to $23.1 Million; Direct Patient Services

$AMSMed

Amadeus IT Group 9-Month Revenue Rises

Amadeus IT Group reported a 3.7% revenue increase to EUR 5.075 billion for the first nine months of fiscal 2026. Net income fell slightly to EUR 1.081 billion, while adjusted profit rose to EUR 1.147 billion. CEO Luis Maroto expects 2026 outlook to be met, likely at the lower end, due to Middle East impacts.

$AMSMed

American Shared Hospital Services Q2 Net Loss Widens to $514,000 Despite Revenue Growth – Minichart

American Shared Hospital Services (NYSE American: AMS) reported a Q2 2026 net loss of $514,000, or $0.07 per diluted share, widening from a $280,000 loss a year earlier, despite revenue rising 19.2% to $8.43 million. Direct patient services drove growth, while gross profit and operating loss worsened. Cash rose to $6.511 million at June 30, 2026, and the company later arranged financing with Fifth Third Bank.